Intrinsic value of NuVasive - NUVA

Previous Close

$53.61

  Intrinsic Value

$21.57

stock screener

  Rating & Target

str. sell

-60%

Previous close

$53.61

 
Intrinsic value

$21.57

 
Up/down potential

-60%

 
Rating

str. sell

We calculate the intrinsic value of NUVA stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  7.00
  6.80
  6.62
  6.46
  6.31
  6.18
  6.06
  5.96
  5.86
  5.77
  5.70
  5.63
  5.56
  5.51
  5.46
  5.41
  5.37
  5.33
  5.30
  5.27
  5.24
  5.22
  5.20
  5.18
  5.16
  5.14
  5.13
  5.12
  5.10
  5.09
Revenue, $m
  1,102
  1,177
  1,255
  1,336
  1,420
  1,508
  1,600
  1,695
  1,794
  1,898
  2,006
  2,119
  2,237
  2,360
  2,489
  2,623
  2,764
  2,912
  3,066
  3,228
  3,397
  3,574
  3,760
  3,955
  4,159
  4,372
  4,597
  4,832
  5,079
  5,337
Variable operating expenses, $m
  954
  1,014
  1,075
  1,139
  1,206
  1,276
  1,348
  1,423
  1,502
  1,584
  1,588
  1,677
  1,771
  1,868
  1,970
  2,077
  2,188
  2,305
  2,427
  2,555
  2,689
  2,829
  2,976
  3,130
  3,292
  3,461
  3,639
  3,825
  4,020
  4,225
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  954
  1,014
  1,075
  1,139
  1,206
  1,276
  1,348
  1,423
  1,502
  1,584
  1,588
  1,677
  1,771
  1,868
  1,970
  2,077
  2,188
  2,305
  2,427
  2,555
  2,689
  2,829
  2,976
  3,130
  3,292
  3,461
  3,639
  3,825
  4,020
  4,225
Operating income, $m
  148
  164
  180
  197
  214
  233
  252
  271
  292
  314
  418
  442
  466
  492
  519
  547
  576
  607
  639
  673
  708
  745
  784
  824
  867
  911
  958
  1,007
  1,058
  1,112
EBITDA, $m
  336
  359
  383
  408
  433
  460
  488
  517
  547
  579
  612
  646
  682
  720
  759
  800
  843
  888
  936
  985
  1,036
  1,091
  1,147
  1,207
  1,269
  1,334
  1,403
  1,474
  1,550
  1,629
Interest expense (income), $m
  13
  37
  40
  44
  48
  53
  57
  61
  66
  71
  76
  82
  87
  93
  99
  105
  112
  119
  126
  134
  142
  150
  159
  168
  178
  188
  198
  209
  221
  233
  246
Earnings before tax, $m
  111
  123
  135
  148
  162
  176
  190
  205
  221
  237
  336
  354
  373
  393
  413
  435
  457
  480
  505
  531
  558
  586
  615
  646
  679
  713
  749
  786
  825
  866
Tax expense, $m
  30
  33
  37
  40
  44
  47
  51
  55
  60
  64
  91
  96
  101
  106
  112
  117
  123
  130
  136
  143
  151
  158
  166
  175
  183
  192
  202
  212
  223
  234
Net income, $m
  81
  90
  99
  108
  118
  128
  139
  150
  161
  173
  246
  259
  272
  287
  302
  317
  334
  351
  369
  387
  407
  428
  449
  472
  496
  520
  546
  574
  602
  633

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,755
  1,874
  1,998
  2,127
  2,262
  2,401
  2,547
  2,699
  2,857
  3,022
  3,194
  3,374
  3,562
  3,758
  3,963
  4,177
  4,402
  4,636
  4,882
  5,140
  5,409
  5,691
  5,987
  6,297
  6,622
  6,963
  7,320
  7,694
  8,087
  8,499
Adjusted assets (=assets-cash), $m
  1,755
  1,874
  1,998
  2,127
  2,262
  2,401
  2,547
  2,699
  2,857
  3,022
  3,194
  3,374
  3,562
  3,758
  3,963
  4,177
  4,402
  4,636
  4,882
  5,140
  5,409
  5,691
  5,987
  6,297
  6,622
  6,963
  7,320
  7,694
  8,087
  8,499
Revenue / Adjusted assets
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
  0.628
Average production assets, $m
  1,066
  1,138
  1,214
  1,292
  1,373
  1,458
  1,547
  1,639
  1,735
  1,835
  1,940
  2,049
  2,163
  2,282
  2,407
  2,537
  2,673
  2,816
  2,965
  3,121
  3,285
  3,456
  3,636
  3,824
  4,021
  4,228
  4,445
  4,672
  4,911
  5,161
Working capital, $m
  184
  197
  210
  223
  237
  252
  267
  283
  300
  317
  335
  354
  374
  394
  416
  438
  462
  486
  512
  539
  567
  597
  628
  660
  694
  730
  768
  807
  848
  891
Total debt, $m
  643
  704
  768
  834
  904
  976
  1,051
  1,129
  1,210
  1,295
  1,384
  1,476
  1,573
  1,674
  1,780
  1,890
  2,006
  2,127
  2,253
  2,386
  2,524
  2,670
  2,822
  2,982
  3,149
  3,325
  3,508
  3,701
  3,904
  4,116
Total liabilities, $m
  904
  965
  1,029
  1,096
  1,165
  1,237
  1,312
  1,390
  1,471
  1,556
  1,645
  1,738
  1,834
  1,935
  2,041
  2,151
  2,267
  2,388
  2,514
  2,647
  2,786
  2,931
  3,083
  3,243
  3,410
  3,586
  3,770
  3,962
  4,165
  4,377
Total equity, $m
  851
  909
  969
  1,032
  1,097
  1,165
  1,235
  1,309
  1,386
  1,466
  1,549
  1,636
  1,727
  1,823
  1,922
  2,026
  2,135
  2,249
  2,368
  2,493
  2,623
  2,760
  2,904
  3,054
  3,212
  3,377
  3,550
  3,732
  3,922
  4,122
Total liabilities and equity, $m
  1,755
  1,874
  1,998
  2,128
  2,262
  2,402
  2,547
  2,699
  2,857
  3,022
  3,194
  3,374
  3,561
  3,758
  3,963
  4,177
  4,402
  4,637
  4,882
  5,140
  5,409
  5,691
  5,987
  6,297
  6,622
  6,963
  7,320
  7,694
  8,087
  8,499
Debt-to-equity ratio
  0.760
  0.770
  0.790
  0.810
  0.820
  0.840
  0.850
  0.860
  0.870
  0.880
  0.890
  0.900
  0.910
  0.920
  0.930
  0.930
  0.940
  0.950
  0.950
  0.960
  0.960
  0.970
  0.970
  0.980
  0.980
  0.980
  0.990
  0.990
  1.000
  1.000
Adjusted equity ratio
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485
  0.485

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  81
  90
  99
  108
  118
  128
  139
  150
  161
  173
  246
  259
  272
  287
  302
  317
  334
  351
  369
  387
  407
  428
  449
  472
  496
  520
  546
  574
  602
  633
Depreciation, amort., depletion, $m
  188
  196
  203
  211
  219
  228
  236
  246
  255
  265
  194
  205
  216
  228
  241
  254
  267
  282
  296
  312
  328
  346
  364
  382
  402
  423
  445
  467
  491
  516
Funds from operations, $m
  270
  285
  302
  319
  337
  356
  375
  396
  417
  439
  440
  464
  489
  515
  542
  571
  601
  632
  665
  700
  736
  773
  813
  854
  898
  943
  991
  1,041
  1,094
  1,149
Change in working capital, $m
  12
  13
  13
  14
  14
  15
  15
  16
  17
  17
  18
  19
  20
  21
  22
  22
  24
  25
  26
  27
  28
  30
  31
  33
  34
  36
  37
  39
  41
  43
Cash from operations, $m
  257
  273
  289
  306
  323
  341
  360
  380
  400
  421
  422
  445
  469
  494
  521
  548
  577
  608
  639
  673
  707
  744
  782
  822
  864
  908
  954
  1,002
  1,052
  1,105
Maintenance CAPEX, $m
  -100
  -107
  -114
  -121
  -129
  -137
  -146
  -155
  -164
  -173
  -184
  -194
  -205
  -216
  -228
  -241
  -254
  -267
  -282
  -296
  -312
  -328
  -346
  -364
  -382
  -402
  -423
  -445
  -467
  -491
New CAPEX, $m
  -70
  -72
  -75
  -78
  -82
  -85
  -88
  -92
  -96
  -100
  -105
  -109
  -114
  -119
  -125
  -130
  -136
  -143
  -149
  -156
  -164
  -171
  -180
  -188
  -197
  -207
  -217
  -227
  -239
  -250
Cash from investing activities, $m
  -170
  -179
  -189
  -199
  -211
  -222
  -234
  -247
  -260
  -273
  -289
  -303
  -319
  -335
  -353
  -371
  -390
  -410
  -431
  -452
  -476
  -499
  -526
  -552
  -579
  -609
  -640
  -672
  -706
  -741
Free cash flow, $m
  88
  94
  100
  106
  112
  119
  126
  133
  140
  148
  133
  142
  150
  159
  168
  178
  187
  198
  209
  220
  232
  244
  257
  270
  284
  299
  314
  330
  347
  364
Issuance/(repayment) of debt, $m
  60
  61
  64
  66
  69
  72
  75
  78
  81
  85
  89
  93
  97
  101
  106
  110
  116
  121
  127
  133
  139
  145
  152
  160
  167
  175
  184
  193
  202
  212
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  60
  61
  64
  66
  69
  72
  75
  78
  81
  85
  89
  93
  97
  101
  106
  110
  116
  121
  127
  133
  139
  145
  152
  160
  167
  175
  184
  193
  202
  212
Total cash flow (excl. dividends), $m
  148
  155
  164
  172
  181
  191
  201
  211
  222
  233
  222
  234
  247
  260
  274
  288
  303
  319
  335
  352
  370
  389
  409
  430
  451
  474
  498
  523
  549
  576
Retained Cash Flow (-), $m
  -56
  -58
  -60
  -63
  -65
  -68
  -71
  -74
  -77
  -80
  -84
  -87
  -91
  -95
  -99
  -104
  -109
  -114
  -119
  -125
  -131
  -137
  -143
  -150
  -158
  -165
  -173
  -182
  -190
  -200
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  23
  24
  26
  28
  29
  31
  33
  35
  37
  39
  42
  44
  47
  49
  52
  55
  58
  61
  64
  67
  71
  75
  79
  83
  87
  91
  96
  101
  106
  112
Cash available for distribution, $m
  91
  97
  104
  110
  116
  123
  130
  137
  145
  153
  139
  147
  156
  165
  174
  184
  194
  205
  216
  228
  240
  252
  265
  279
  294
  309
  325
  341
  358
  377
Discount rate, %
  6.20
  6.51
  6.84
  7.18
  7.54
  7.91
  8.31
  8.72
  9.16
  9.62
  10.10
  10.60
  11.13
  11.69
  12.28
  12.89
  13.53
  14.21
  14.92
  15.67
  16.45
  17.27
  18.14
  19.04
  20.00
  21.00
  22.05
  23.15
  24.30
  25.52
PV of cash for distribution, $m
  86
  86
  85
  83
  81
  78
  74
  70
  66
  61
  48
  44
  39
  35
  31
  26
  22
  19
  15
  12
  10
  8
  6
  4
  3
  2
  1
  1
  1
  0
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

FINANCIAL RATIOS  of  NuVasive (NUVA)

Valuation Ratios
P/E Ratio 73.1
Price to Sales 2.8
Price to Book 3.9
Price to Tangible Book
Price to Cash Flow 17.3
Price to Free Cash Flow 43.6
Growth Rates
Sales Growth Rate 18.6%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -13%
Cap. Spend. - 3 Yr. Gr. Rate 14.4%
Financial Strength
Quick Ratio 2
Current Ratio 0
LT Debt to Equity 81.2%
Total Debt to Equity 90.1%
Interest Coverage 6
Management Effectiveness
Return On Assets 3.1%
Ret/ On Assets - 3 Yr. Avg. 2.9%
Return On Total Capital 3.1%
Ret/ On T. Cap. - 3 Yr. Avg. 2.6%
Return On Equity 5.3%
Return On Equity - 3 Yr. Avg. 4.1%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 75.1%
Gross Margin - 3 Yr. Avg. 75.7%
EBITDA Margin 18.8%
EBITDA Margin - 3 Yr. Avg. 16.9%
Operating Margin 12.8%
Oper. Margin - 3 Yr. Avg. 10.8%
Pre-Tax Margin 6.8%
Pre-Tax Margin - 3 Yr. Avg. 6.4%
Net Profit Margin 3.8%
Net Profit Margin - 3 Yr. Avg. 3.3%
Effective Tax Rate 46.2%
Eff/ Tax Rate - 3 Yr. Avg. 8.2%
Payout Ratio 0%

NUVA stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the NUVA stock intrinsic value calculation we used $1030 million for the last fiscal year's total revenue generated by NuVasive. The default revenue input number comes from 2017 income statement of NuVasive. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our NUVA stock valuation model: a) initial revenue growth rate of 7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 6.2%, whose default value for NUVA is calculated based on our internal credit rating of NuVasive, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of NuVasive.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of NUVA stock the variable cost ratio is equal to 87.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for NUVA stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 6.3% for NuVasive.

Corporate tax rate of 27% is the nominal tax rate for NuVasive. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the NUVA stock is equal to 2.2%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for NUVA are equal to 96.7%.

Life of production assets of 10 years is the average useful life of capital assets used in NuVasive operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for NUVA is equal to 16.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $795 million for NuVasive - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 51 million for NuVasive is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of NuVasive at the current share price and the inputted number of shares is $2.7 billion.

RELATED COMPANIES Price Int.Val. Rating
ZBH Zimmer Biomet 111.66 61.79  sell
GMED Globus Medical 52.65 21.51  str.sell
OFIX Orthofix Inter 60.02 71.28  buy
KTWO K2M Group Hold 21.37 0.59  str.sell
RTIX RTI Surgical 4.75 0.47  str.sell
SYK Stryker 174.30 73.42  str.sell
SPNE SeaSpine Holdi 12.78 1.48  str.sell

COMPANY NEWS

▶ 3 Stocks to Tap the Minimally-Invasive Surgery Market Boom   [Jun-28-18 02:20PM  InvestorPlace]
▶ A Look At The Fair Value Of NuVasive Inc (NASDAQ:NUVA)   [Jun-21-18 10:47AM  Simply Wall St.]
▶ NuVasive Announces Key Finance Appointments   [Jun-11-18 08:30AM  PR Newswire]
▶ NuVasive: 1Q Earnings Snapshot   [May-01-18 04:14PM  Associated Press]
▶ NuVasive to Participate in Investor Events in March 2018   [Mar-05-18 04:02PM  PR Newswire]
▶ NuVasive Sees a Stronger 2018   [Feb-26-18 05:45PM  Motley Fool]
▶ NuVasive meets 4Q profit forecasts   [04:39PM  Associated Press]
▶ NuVasive, Inc. to Host Earnings Call   [12:15PM  ACCESSWIRE]
▶ John DeFord To Join NuVasive Board Of Directors   [Feb-08-18 04:05PM  PR Newswire]
▶ Why Mizuho Securities Upgraded Teva Pharmaceutical to a Buy   [Jan-12-18 09:45AM  Market Realist]
▶ Here's What Pressured NuVasive, Inc. Stock Today   [Jan-08-18 02:26PM  Motley Fool]
▶ Medtech Player Bounds On Upgrade Amid Tax Reform, Acquisitions   [Jan-04-18 04:31PM  Investor's Business Daily]
▶ ETFs with exposure to NuVasive, Inc. : December 28, 2017   [Dec-28-17 12:31PM  Capital Cube]
▶ Medical device maker says savings from new tax law to fuel innovation and growth   [Dec-21-17 01:46PM  American City Business Journals]
▶ NuVasive To Acquire SafePassage   [Dec-12-17 04:02PM  PR Newswire]
▶ ETFs with exposure to NuVasive, Inc. : November 6, 2017   [Nov-06-17 12:12PM  Capital Cube]
▶ ETFs with exposure to NuVasive, Inc. : October 27, 2017   [Oct-27-17 11:07AM  Capital Cube]
▶ Here's Why NuVasive, Inc. Popped Today   [04:03PM  Motley Fool]
▶ NuVasive's Sluggish Sales Growth Prompts Buybacks   [Oct-24-17 07:19PM  Motley Fool]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.